ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. 더 보기
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference...
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and...
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.34 | 3.53798126951 | 9.61 | 10.22 | 8.74 | 460218 | 9.46221856 | CS |
4 | -7.03 | -41.4016489988 | 16.98 | 17.52 | 8.74 | 918744 | 11.28316119 | CS |
12 | -6.39 | -39.1064871481 | 16.34 | 18.13 | 8.74 | 545510 | 13.37594027 | CS |
26 | -2.29 | -18.7091503268 | 12.24 | 18.75 | 8.74 | 481163 | 14.4235375 | CS |
52 | 0.15 | 1.5306122449 | 9.8 | 18.75 | 8.2 | 430292 | 12.6512133 | CS |
156 | -16.99 | -63.0660727543 | 26.94 | 52.43 | 8.2 | 388535 | 19.67689365 | CS |
260 | -9.75 | -49.4923857868 | 19.7 | 52.43 | 8.2 | 351607 | 21.38437739 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관